Bayer AG
BAYN: XETR (DEU)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€54.00 | Qywcxq | Hhjs |
Bayer Holds a Solid Portfolio of Crop and Healthcare Products, but Patent Pressures Remain
Business Strategy and Outlook
Largely on the basis of the strong competitive advantages of the healthcare group and to a lesser extent the crop science business, we believe Bayer has created a narrow economic moat. Bayer is evaluating the divestitures of the crop science and consumer healthcare businesses, which appear to hold few synergies with the prescription drug business.